Integrated Filing — IndAS



General information about company

Scrip Code 524404
NSE Symbol MARKSANS
MSEI Symbol NOTLISTED
ISIN INE750C01026
Name of company Marksans Pharma Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 12-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 31-07-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Pharmaceutical Formulation
Start date and time of board meeting 12-08-2026   10:50:00
End date and time of board meeting 12-08-2026   12:10:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 84,079.60 84,079.60
Other income 2,540.40 2,540.40
Total income 86,620.00 86,620.00
2 Expenses
(a) Cost of materials consumed 22,066.90 22,066.90
(b) Purchases of stock-in-trade 13,844.90 13,844.90
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1,565.20) (1,565.20)
(d) Employee benefit expense 11,429.40 11,429.40
(e) Finance costs 700.40 700.40
(f) Depreciation, depletion and amortisation expense 2,486.40 2,486.40
(f) Other Expenses
1 Other Expenses 17,000.10 17,000.10
Total other expenses 17,000.10 17,000.10
Total expenses 65,962.90 65,962.90
3 Total profit before exceptional items and tax 20,657.10 20,657.10
4 Exceptional items 0.00 0.00
5 Total profit before tax 20,657.10 20,657.10
6 Tax expense
7 Current tax 5,188.40 5,188.40
8 Deferred tax (472.00) (472.00)
9 Total tax expenses 4,716.40 4,716.40
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 15,940.70 15,940.70
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 15,940.70 15,940.70
17 Other comprehensive income net of taxes 1,702.40 1,702.40
18 Total Comprehensive Income for the period 17,643.10 17,643.10
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 15,716.70 15,716.70
Total profit or loss, attributable to non-controlling interests 224.00 224.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 17,385.70 17,385.70
Total comprehensive income for the period attributable to owners of parent non-controlling interests 257.40 257.40
21 Details of equity share capital
Paid-up equity share capital 4,531.60 4,531.60
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 3.47 3.47
Diluted earnings (loss) per share from continuing operations 3.47 3.47
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 3.47 3.47
Diluted earnings (loss) per share from continuing and discontinued operations 3.47 3.47
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The consolidated unaudited financial results of the Company for the quarter ended 30 June 2026 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12 August 2026. The Statutory Auditors of the Company have carried out a limited review of the above results in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 ('the Regulations'), as amended and expressed an unmodified conclusion. 2. The consolidated unaudited financial results of the Company have been prepared in accordance with the recognition and measurement principles laid dwn in Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulations. 3. The figures for the quarter ended 31 March 2026 represents the derived figures between the audited figures in respect of full financial year ended 31 Mach 2026 and the unaudited published year-to-date figures up to 31 December 2025, being the date of the end of the third quarter of the financial year which were subjected to limited review by the statutory auditor of the Company. 4. The Group has a single business segment 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments. 5. Other income net includes net gain on foreign exchange differences amounting to Rs. 120.01 millions for the quarter ended 30 June 2026 (31 March 2026: net gain of Rs. 247.99 millions, 30 June 2025: net loss of Rs. 38.93 millions, year ended 31 March 2026: net gain of Rs. 500.95 millions). 6. During the current quarter, the Company has acquired 100% share capital of QliniQ B.V., a company based in Netherlands, for a consideration of EUR 7.50 Million. QliniQ B.V. specializes in bringing innovative healthcare solutions to the Dutch market through the marketing and distribution of prescription medicines and mdical devices. QliniQ B.V. is a subsidiary of the company w.e.f. 1 April 2026. As per Ind AS 103 on ‘Business Combinations’, purchase consideration has been allocated on a provisional basis, pending final determination of the fair value of the acquired assets and liabilities. 7. Subsequent to the quarter ended 30 June 2026, the Company entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany-based pharmaceutical company with frontend sales, marketing, and distribution capabilities across German healthcare market, for a cash consideration of EUR 1.10 Million. The acquisition was subsequently completed, following which ABCnow GmbH became a wholly owned subsidiary of the Company. 8.During the quarter ended 30 June 2026, the company granted 300,000 stock options under the Marksans Employees Stock Option Scheme 2024 to eligible employees of the Company and its subsidiay companies. Each stock option is exercisable into one equity share of the Company having a face value of Rs.1 each.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-06-2026 30-06-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurements of the net defined benefit Plans 34.80 34.80
Total Amount of items that will not be reclassified to profit and loss 34.80
2 Income tax relating to items that will not be reclassified to profit or loss 8.80 8.80
3 Amount of items that will be reclassified to profit and loss
1 Foreign currency translation reserve (net) 1,676.40 1,676.40
Total Amount of items that will be reclassified to profit and loss 1,676.40
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 1,702.40 1,702.40





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M S K A & Associates Yes 31-07-2027